Acalabrutinib - Acerta Pharma

Drug Profile

Acalabrutinib - Acerta Pharma

Alternative Names: ACP-196; CALQUENCE

Latest Information Update: 03 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acerta Pharma
  • Developer Acerta Pharma; AstraZeneca; Biologics Inc; Merck Sharp & Dohme; University Hospital Southampton NHS Foundation Trust
  • Class Antineoplastics; Benzamides; Heavy metals; Imidazoles; Pyrazines; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Waldenstrom's macroglobulinaemia; Mantle-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mantle-cell lymphoma
  • Phase III Chronic lymphocytic leukaemia
  • Phase II Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Rheumatoid arthritis; Waldenstrom's macroglobulinaemia
  • Phase I/II B cell lymphoma; B cell prolymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Glioblastoma; Multiple myeloma
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Sep 2018 Phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, Second-line therapy or greater) is ongoing USA (Acerta Pharma pipeline, September 2018)
  • 30 Jul 2018 Dana-Farber Cancer Institute, Acerta Pharma and Genentech initiate a phase II trial for Chronic lymphocytic leukaemia (Combination therapy) in USA (NCT03580928)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top